National Institutes of Health

Description

The objective of this NOFO is to provide evidence for the optimal treatment of ADHD in adults, given its relatively recent acceptance as a formal diagnostic category. While stimulant drugs offer the advantages of rapid onset of action and history of efficacy, the risk of adverse effects, dependence, misuse, and diversion, along with recent medication shortages, underscore the importance of studying evidence-based complementary and alternative approaches when indicated. Clinical trials testing non-stimulant medications, psychosocial interventions, and device-based approaches, sequentially or in combination, to augment or replace stimulants in situations where stimulant monotherapy is insufficiently effective, difficult to tolerate, or undesirable, in the acute and post-acute treatment of ADHD in adults, or in preventing the transition of ADHD symptoms from adolescence to adulthood, will be supported by this NOFO.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH Grants Information<br/>grantsinfo@nih.gov
grantsinfo@nih.gov